Free
Perioperative Medicine  |   May 2009
Reversal of Profound Neuromuscular Block by Sugammadex Administered Three Minutes after Rocuronium: A Comparison with Spontaneous Recovery from Succinylcholine
Author Affiliations & Notes
  • Chingmuh Lee, M.D.
    *
  • Jonathan S. Jahr, M.D.
  • Keith A. Candiotti, M.D.
  • Brian Warriner, M.D.
    §
  • Mark H. Zornow, M.D.
  • Mohamed Naguib, M.D.
    #
  • * Professor Emeritus, Department of Anesthesiology, David Geffen School of Medicine at the University of California Los Angeles, Harbor/UCLA Medical Center, Torrance, California. † Professor of Clinical Anesthesiology, David Geffen School of Medicine at the University of California Los Angeles, Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, California. ‡ Associate Professor of Clinical Anesthesiology and Internal Medicine; Director of Clinical Research; Chief, Division of Perioperative Medicine; University of Miami School of Medicine, Miami, Florida. § Professor and Head, University of British Columbia Department of Anesthesiology, Pharmacology and Therapeutics, St. Paul's Hospital, Vancouver, British Columbia, Canada. ∥ Professor of Anesthesiology and Perioperative Medicine, Department of Anesthesiology, Oregon Health and Science University, Portland, Oregon. # Professor, Department of Anesthesiology and Pain Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Article Information
Perioperative Medicine / Neuromuscular Diseases and Drugs
Perioperative Medicine   |   May 2009
Reversal of Profound Neuromuscular Block by Sugammadex Administered Three Minutes after Rocuronium: A Comparison with Spontaneous Recovery from Succinylcholine
Anesthesiology 5 2009, Vol.110, 1020-1025. doi:10.1097/ALN.0b013e31819dabb0
Anesthesiology 5 2009, Vol.110, 1020-1025. doi:10.1097/ALN.0b013e31819dabb0
SUCCINYLCHOLINE is a depolarizing neuromuscular blocking agent (NMBA) used for short-term muscle relaxation, most often first-line to facilitate tracheal intubation. Because of its fast onset and short duration of action, it has considerable use in emergency situations where a neuromuscular block must be induced and the airway secured quickly to protect against aspiration of gastric contents.1–3 A short duration of action is essential in cases of a difficult airway where the patient cannot be intubated or ventilated and rapid restoration of spontaneous respiration is crucial.2,4 
Succinylcholine has the shortest duration of action of all currently available NMBAs.5 At 1 mg/kg it typically provides a complete block in approximately 1 min and recovery in 6 to 9 min (first train-of-four twitch [T1] to 10%) or 10 to 13 min (T1to 90%).6–8 Succinylcholine is associated with a variety of adverse events and contraindications.9–15 Unfortunately, decades of efforts to develop a new nondepolarizing NMBA both safer and shorter-acting than succinylcholine have failed.16 
The nondepolarizing NMBA rocuronium is also indicated to facilitate tracheal intubation during routine and rapid-sequence intubation, especially where succinylcholine is contraindicated.1Succinylcholine (1 mg/kg) reliably provides excellent to acceptable intubating conditions, as compared with 0.6 to 0.7 mg/kg rocuronium, although no significant differences have been observed between 1 mg/kg succinylcholine 0.9 to 1.2 mg/kg rocuronium.2 Rocuronium (0.6 to 1.2 mg/kg) typically completes a neuromuscular block in < 2 min, as compared with < 1 min on average for 1 mg/kg succinylcholine.17 However, higher doses of rocuronium have a long duration of action; this is inappropriate in situations where rapid recovery of neuromuscular function is required.17 In addition, anticholinesterases readily expedite recovery from nondepolarizing block but are ineffective for the reversal of a profound block, and present a significant side effect profile.12,18 
A plausible new approach to both rapid onset and rapid recovery of neuromuscular block might involve blocking with high-dose rocuronium and reversal using high-dose sugammadex. Studies in surgical patients have shown that 0.5 to 16 mg/kg sugammadex provides well-tolerated and dose-dependent rapid reversal of shallow19–22 and profound23–25 rocuronium-induced neuromuscular block.
Evidence suggests that sugammadex will be efficacious against high-dose rocuronium soon after the onset of neuromuscular block, with time to reversal of block at least comparable with spontaneous recovery from succinylcholine, but this requires confirmation.25,26 In this study, the efficacy and safety of 16 mg/kg sugammadex given 3 min after 1.2 mg/kg rocuronium for reversal of profound neuromuscular block was compared with that of spontaneous recovery from 1 mg/kg succinylcholine-induced block.
Materials and Methods
This multicenter, randomized, safety-assessor–blinded, parallel-group, active-controlled Phase IIIa trial, known as the Spectrum study, was conducted in 11 centers: 9 in the United States and 2 in Canada. The study protocol was approved by the Institutional Review Committee for each center and was conducted in accordance with the Declaration of Helsinki (current revision), the International Conference on Harmonization guidelines, Good Clinical Practice, and current regulatory requirements. Written informed consent was obtained from all participating patients. Eligible patients enrolled into the trial were assigned a subject allocation number and randomized to a treatment. Patients were recruited by investigators and/or their staff.
Patients
Patients aged 18 to 65 yr, American Society of Anesthesiologists Class I or II, were eligible if they had a body mass index < 30 kg/m2, were scheduled to undergo an elective surgical procedure under general anesthesia in the supine position requiring a short duration of neuromuscular relaxation for which rocuronium or succinylcholine was indicated, and required tracheal intubation. Exclusion criteria included ischemic heart disease or a history of myocardial infarction within the last year; a (family) history of malignant hyperthermia; significant renal dysfunction; known or suspected neuromuscular disorders; allergies to narcotics, muscle relaxants, midazolam, anesthetics, or other medications used during general anesthesia; and patients where difficult intubation was expected upon physical examination. Female patients who were pregnant, breast-feeding, or of childbearing potential and not using adequate contraception (pregnancy test performed to exclude pregnancy) were excluded. Patients receiving medication known to interfere with neuromuscular function (e.g.,  aminoglycosides, anticonvulsants, or magnesium) were also excluded, as were any participants in a previous sugammadex trial or any other trial not approved by the sponsor within 30 days before entering this trial.
Study Design
The trial comprised a screening period of up to 7 days before treatment, a perianesthetic period (randomization to postanesthetic period), and a postanesthetic period comprising a postoperative visit by a safety assessor (≥ 10 h after study drug administration), and a follow-up surveillance up to 7 days after surgery. Adverse events (AEs) and serious AEs were monitored during the postoperative visit and at follow-up by the blinded assessor, who did not perform randomization nor prepare or administer trial medication.
Patients were premedicated with intravenous midazolam, up to 2 mg as needed, upon arrival at the operating room. Noninvasive automatic monitoring of arterial blood pressure, oxygen saturation, and electrocardiography were applied.
Anesthesia was induced and maintained with an intravenous opioid and propofol and other agents/medications at a concentration/dose range according to clinical need and local practice. No inhalational anesthetic was used during the neuromuscular monitoring period. Upon induction, patients received either 1.2 mg/kg rocuronium or 1 mg/kg succinylcholine, administered within 10 s as a single bolus into a fast-running intravenous infusion. At 1 min, the endotracheal tube was inserted. Sugammadex (16 mg/kg) was administered 3 min after the start of rocuronium administration, also as a bolus within 10 s into a fast-running intravenous infusion. Patients receiving succinylcholine were allowed to recover spontaneously. After surgery, patients were allowed to recover from anesthesia and transferred to the postoperative recovery room.
Neuromuscular monitoring was performed using the TOF-Watch SX (Schering-Plough, Dublin, Ireland). The ulnar nerve was supramaximally stimulated near the wrist with square pulses of 0.2 ms duration, delivered as train-of-four pulses of 2 Hz, at intervals of 15 s. The resulting contractions of the adductor pollicis muscle were quantified acceleromyographically (TOFMON 1.2, Schering-Plough, Oss, The Netherlands). Stabilization, calibration, and baseline responses were recorded upon anesthesia induction, and neuromuscular monitoring was continued until the end of anesthesia, or at least until recovery of the T4/T1ratio to 0.9. The final T1value was calculated as the mean of three consecutive T1values after T1had reached a plateau, when there was no or little further increase in its amplitude.
Patients were assessed for reoccurrence of neuromuscular block (decrease in T4/T1to < 0.8 in the rocuronium-sugammadex group). Patients were also assessed for clinical signs of muscle weakness before transfer to and discharge from the recovery room. Central body temperature was maintained at ≥ 35°C, and skin temperature at the monitoring site at ≥ 32°C. Pulse oximetry and respiratory rate monitoring were continued for ≥ 60 min in the recovery room.
Efficacy Variables
The primary efficacy variable was time from the start of administration of rocuronium or succinylcholine to recovery of T1to 10% of the baseline value. Additional efficacy variables included time from start of administration of rocuronium or succinylcholine to recovery of T1to 90%, and standard clinical signs of anesthetic and neuromuscular recovery before transfer to and discharge from the recovery room. Time from start of sugammadex administration to recovery of T4/T1to 0.7, 0.8, and 0.9 was also recorded.
Safety Assessment
An AE was defined as any untoward medical occurrence in a patient receiving a pharmaceutical product. A serious AE was defined as any AE that at any dose resulted in death, was life-threatening, required prolonged hospitalization, or resulted in persistent disability. AEs were categorized using MedDRA version 9.1 (International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland).
Physical examination was performed at preoperative screening and postoperative visits. Blood pressure and heart rate were recorded at regular intervals throughout. Three 10-ml blood samples were collected per patient for biochemistry and hematology assessment; just before relaxant administration, 4 to 6 h after administration, and at the postoperative visit (at least 10 h after relaxant administration). Urine samples were collected before surgery and at the postanesthetic visit for subsequent urinalysis.
Statistical Analysis
A sample size of 55 patients per treatment group was predetermined to provide 90% power to detect a between-group difference in time to T1= 10% of > 1 min, assuming up to 5% dropout from the intent-to-treat population (all patients randomized based on treatment intent, with ≥ 1 postbaseline efficacy assessment) and uniformity among study sites.
The primary efficacy analysis (intent-to-treat population) included imputation of missing recovery times. For imputation of missing times from the start of relaxant administration to recovery of T1to 10% and T1to 90%, a conservative approach towards sugammadex was applied. In the case of a missing recovery time in the rocuronium-sugammadex group (for example, time from administration of rocuronium to recovery of T1to 90%), the 95th percentile of the available times to T190% in the sugammadex group was imputed for the missing recovery time. For a missing recovery time in the succinylcholine group (for example, time from administration of succinylcholine to recovery of T1to 90%), the 5th percentile of the available times to T1= 90% in the succinylcholine group was imputed. The same procedure was applied for imputation of missing times from relaxant administration to recovery of T1to 10%. Times to T1= 10% and T1= 90% were compared using two-way analysis of variance. P  values, estimated between-group differences and the corresponding two-sided 95% CIs were calculated.
Results
The trial was conducted between February and August 2006. Overall, 115 patients were enrolled and randomized (rocuronium-sugammadex, n = 57; succinylcholine, n = 58); 5 patients withdrew before administration of the study drug (n = 2 and n = 3, respectively) and were excluded. The intent-to-treat population thus comprised 110 patients, 55 in each group (fig. 1). However, three patients received medication inconsistent with randomization; one patient in the rocuronium-sugammadex group received succinylcholine, while two patients in the succinylcholine group received rocuronium-sugammadex. Based on actual treatment received, the treated population comprised 56 patients in the rocuronium-sugammadex group and 54 in the succinylcholine group. All treated patients had ≥ 1 postbaseline efficacy value. The opioid used most was fentanyl. The rocuronium-sugammadex and succinylcholine groups were generally comparable regarding baseline characteristics. Patients were of respective mean ages 42 yr (rocuronium-sugammadex) and 41 yr (succinylcholine) (range, 18 to 65 yr), body mass index was 25 kg/m2in each group, and most patients were female (59 and 57%), of American Society of Anesthesiologists Class II (59 and 69%), and Caucasian (73 and 83%). Demographic variables were consistent across participating medical centers.
Fig. 1. Patient flow through the study. * According to the randomization schedule, this patient should have received rocuronium-sugammadex, but in error received succinylcholine. The patient was included in the succinylcholinetreated population, but in the intent-totreat population for rocuronium-sugammadex. † According to the randomization schedule, these two patients should have received succinylcholine, but in error received rocuronium-sugammadex. They were included in the rocuronium-sugammadex–treated population, but in the intent-totreat population for succinylcholine. 
Fig. 1. Patient flow through the study. * According to the randomization schedule, this patient should have received rocuronium-sugammadex, but in error received succinylcholine. The patient was included in the succinylcholinetreated population, but in the intent-totreat population for rocuronium-sugammadex. † According to the randomization schedule, these two patients should have received succinylcholine, but in error received rocuronium-sugammadex. They were included in the rocuronium-sugammadex–treated population, but in the intent-totreat population for succinylcholine. 
Fig. 1. Patient flow through the study. * According to the randomization schedule, this patient should have received rocuronium-sugammadex, but in error received succinylcholine. The patient was included in the succinylcholinetreated population, but in the intent-totreat population for rocuronium-sugammadex. † According to the randomization schedule, these two patients should have received succinylcholine, but in error received rocuronium-sugammadex. They were included in the rocuronium-sugammadex–treated population, but in the intent-totreat population for succinylcholine. 
×
Efficacy
Mean (SD) time to recovery of T1to 10% from the start of NMBA administration was significantly faster for rocuronium-sugammadex (1.2 mg/kg rocuronium; 16 mg/kg sugammadex), as compared with 1 mg/kg succinylcholine (4.4 [0.7]vs.  . 7.1 [1.6] min, P  < 0.001), with a treatment difference of −2.7 min (95% CI, −3.1 to −2.2 min). Mean (SD) time to recovery of T1to 90% was also significantly faster with rocuronium-sugammadex (6.2 [1.8] min), as compared with succinylcholine (10.9 [2.4] min, P  < 0.001), with a treatment difference of −4.6 min (95% CI, −5.5 to −3.8 min). These data include imputed values (three patients); findings were similar without imputed cases. Similar trends were apparent for median time to recovery of T1to 10% and 90% (table 1). Timed from rocuronium administration, mean (SD) time to recovery of T4/T1to 0.7, 0.8, and 0.9 was 4.4 (0.7), 4.6 (1.1), and 5.4 (2.2) min, respectively.
Table 1. Time (min) from Start of Administration of Neuromuscular Blocking Agent to Recovery of T1to 10% and T1to 90% 
Image not available
Table 1. Time (min) from Start of Administration of Neuromuscular Blocking Agent to Recovery of T1to 10% and T1to 90% 
×
Timed from sugammadex administration, 3.1 (0.2) min after rocuronium, mean (SD) time to recovery of T1to 10% was 1.2 (0.5) min, and to 90% was 2.9 (1.7) min. Mean (SD) time to recovery of T4/T1to 0.7, 0.8, and 0.9 was 1.3 (0.6), 1.5 (1.1), and 2.2 (2.2) min, respectively. Overall, 87% of patients (47 of 54) showed recovery of the T4/T1to 0.9 by 3 min, 52% between 1 to 2 min, and 13% within 1 min after sugammadex administration.
Clinical signs of recovery were comparable between treatment groups. Before transfer to the recovery room, approximately 50% of patients in both groups were awake and oriented; this increased to > 90% at discharge from the recovery room. No patient exhibited clinical signs of muscle weakness after extubation.
Safety
Both treatments were well tolerated. Overall, 93% of patients in the rocuronium-sugammadex group and 94% of patients in the succinylcholine group had ≥ 1 AE. The most common AEs, respectively, in these groups were procedural pain (57.1 vs.  48.1%), and nausea (28.6 vs.  37.0%) (table 2). One patient in the succinylcholine group experienced a serious AE (pelvic hematoma). There were no deaths or difficult intubations.
Table 2. Number of Patients with at Least One Adverse Event Regardless of Relationship to Study Drug 
Image not available
Table 2. Number of Patients with at Least One Adverse Event Regardless of Relationship to Study Drug 
×
There were no clinically meaningful differences between treatment groups in laboratory parameters, physical findings, or vital signs; and no interaction of sugammadex with any compound other than rocuronium was observed.
Discussion
As the primary endpoint, we used recovery of T1to 10% (instead of T4/T1) for its simplicity, its common usefulness between depolarizing and nondepolarizing relaxants, and because the T4/T1ratio has uncertain meaning regarding a single dose of succinylcholine.9 The observed times to spontaneous recovery of T1to 10% and to 90% from succinylcholine-induced block are consistent with previous reports for the same dose of succinylcholine (1 mg/kg).27,28 While lower doses of succinylcholine may also provide adequate conditions for intubation,28–30 higher doses are reported to provide excellent intubation conditions.30 Although our study may be limited by the fact that the rocuronium-sugammadex group was compared against only one dose of succinylcholine (1 mg/kg), this dose of succinylcholine is the most commonly used dose for rapid-sequence induction30 and was thus considered appropriate for this study.
At the doses tested, our findings show that with sugammadex, the mean times to recovery from profound rocuronium-induced neuromuscular block were 4.4 min (T1to 10%) and 6.2 min (T1to 90%), significantly shorter than the respective times to spontaneous recovery from succinylcholine-induced block (7.1 and 10.9 min). These times represent a saving of 2.7 and 4.6 min, respectively, for T1to reach 10% and 90%, favoring sugammadex-induced reversal. While a weakness in our study is the fact that three patients received the incorrect drug in error (one received succinylcholine and two received rocuronium-sugammadex), these random errors had no impact on the overall efficacy findings. If measured from the start of sugammadex administration, the reversal times became even shorter, 1.2 and 2.9 min, respectively.
The timing of sugammadex administration in this study, i.e.  , 3 min after rocuronium administration, was selected to imitate a real-life situation in which two attempts to intubate have failed. A factor that could potentially enhance treatment differences relates to normal practice, where the intubation dose is very likely less than 1.2 mg/kg of rocuronium.
Rocuronium is currently indicated in approximately 25% of rapid-sequence induction cases in the emergency department.31,32 Our results suggest that sugammadex may have considerable use in such a setting.
In conclusion, reversal of profound high-dose rocuronium-induced neuromuscular block (1.2 mg/kg) with sugammadex (16 mg/kg) was significantly faster than spontaneous recovery from succinylcholine (1 mg/kg). Sugammadex reversal of rocuronium may be useful should unexpected need for immediate restoration of neuromuscular function arise.
The authors thank the staff and coinvestigators at participating centers and the following investigators who collaborated on the study: Francois Donati, M.D., Ph.D., Professor, Department of Anesthesiology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada; Scott B. Groudine, M.D., Professor, Department of Anesthesiology, Albany Medical Center Hospital, Albany, New York; Joel O. Johnson, M.D., Ph.D., Professor, Department of Anesthesiology and Perioperative Medicine, University of Missouri Health Care, Columbia, Missouri; Michael W. Jopling, M.D., Chairman, Department of Anesthesiology, Mount Carmel St. Ann's Hospital, Westerville, Ohio; Aaron F. Kopman, M.D., Professor, Department of Anesthesiology, St. Vincent's Hospital and Medical Center, New York, New York; Mark E. Hudson, M.D., Associate Professor, Department of Anesthesiology, University of Pennsylvania Medical Center-Shadyside Hospital, Pittsburgh, Pennsylvania; Harold S. Minkowitz, M.D., Staff Anesthesiologist, Department of Anesthesiology, Memorial Hermann-Memorial City Hospital, Houston, Texas.
Statistical analysis was performed by René A. Kroon, M.Sc., Biostatistician, Schering-Plough, Oss, The Netherlands, and editorial assistance was provided by Carl V. Felton, Ph.D., Senior Medical Writer, Prime Medica, Knutsford, Cheshire, United Kingdom.
References
Cantineau JP, Tazarourte K, Merckx P, Martin L, Reynaud P, Berson C, Bertrand C, Aussavy F, Lepresle E, Pentier C, Duvaldestin P: Tracheal intubation in prehospital resuscitation: Importance of rapid-sequence induction anesthesia. Ann Fr Anesth Reanim 1997; 16:878–84Cantineau, JP Tazarourte, K Merckx, P Martin, L Reynaud, P Berson, C Bertrand, C Aussavy, F Lepresle, E Pentier, C Duvaldestin, P
Perry JJ, Lee JS, Sillberg VAH, Wells GA: Rocuronium versus  succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2008; 2:CD002788.Perry, JJ Lee, JS Sillberg, VAH Wells, GA
Laurin EG, Sakles JC, Panacek EA, Rantapaa AA, Redd J: A comparison of succinylcholine and rocuronium for rapid-sequence intubation of emergency department patients. Acad Emerg Med 2000; 7:1362–9Laurin, EG Sakles, JC Panacek, EA Rantapaa, AA Redd, J
Huizinga AC, Vandenbrom RH, Wierda JM, Hommes FD, Hennis PJ: Intubating conditions and onset of neuromuscular block of rocuronium (org 9426); a comparison with suxamethonium. Acta Anaesthesiol Scand 1992; 36:463–8Huizinga, AC Vandenbrom, RH Wierda, JM Hommes, FD Hennis, PJ
Combs JM, Combs GN: A literature review of the newest muscle relaxant: ORG9426. CRNA 1994; 5:104–12Combs, JM Combs, GN
Katz RL, Ryan JF: The neuromuscular effects of suxamethonium in man. Br J Anaesth 1969; 41:381–90Katz, RL Ryan, JF
Vanlinthout LE, van Egmond J, de Boo T, Lerou JG, Wevers RA, Booij LH: Factors affecting magnitude and time course of neuromuscular block produced by suxamethonium. Br J Anaesth 1992; 69:29–35Vanlinthout, LE van Egmond, J de Boo, T Lerou, JG Wevers, RA Booij, LH
Kopman AF, Zhaku B, Lai KS: The “intubating dose” of succinylcholine: The effect of decreasing doses on recovery time. Anesthesiology 2003; 99:1050–4Kopman, AF Zhaku, B Lai, KS
Lee C, Katz RL: Neuromuscular pharmacology: A clinical update and commentary. Br J Anaesth 1980; 52:173–88Lee, C Katz, RL
Henderson WA: Succinylcholine-induced cardiac arrest in unsuspected Duchenne muscular dystrophy. Can Anaesth Soc J 1984; 31:444–6Henderson, WA
Ward RJ, Eisele JW, Reay DT, Horton WG: Hemolysis and hyperkalemia complicate malignant hyperpyrexia during anesthetic death. J Forensic Sci 1986; 31:543–5Ward, RJ Eisele, JW Reay, DT Horton, WG
Hunter JM: New neuromuscular blocking drugs. N Engl J Med 1995; 332:1691–9Hunter, JM
Naguib M, Magboul MM: Adverse effects of neuromuscular blockers and their antagonists. Drug Saf 1998; 18:99–116Naguib, M Magboul, MM
Miller R: Will succinylcholine ever disappear? Anesth Anal 2004; 98:1674–5Miller, R
Lebowitz PW, Ramsey FM: Muscle relaxants. Clin Anesth 1989; 1:344–6Lebowitz, PW Ramsey, FM
Gyermek L, Lee C, Cho Y, Nguyen NB, Tsai SK: Neuromuscular pharmacology of TAAC3, a new nondepolarizing muscle relaxant with rapid onset and ultra short duration of action. Anesth Analg 2002; 94:879–85Gyermek, L Lee, C Cho, Y Nguyen, NB Tsai, SK
Magorian T, Flannery KB, Miller RD: Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. Anesthesiology 1993; 79:913–8Magorian, T Flannery, KB Miller, RD
Zhang M-Q: Drug-specific cyclodextrins: The future of rapid neuromuscular block reversal. Drugs Future 2003;28:347–54Zhang, M-Q
Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J: Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: A dose-finding and safety study. Anesthesiology 2006; 104:667–74Sorgenfrei, IF Norrild, K Larsen, PB Stensballe, J Ostergaard, D Prins, ME Viby-Mogensen, J
Shields M, Giovanelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y: Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96:36–43Shields, M Giovanelli, M Mirakhur, RK Moppett, I Adams, J Hermens, Y
Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, Demeyer I: Sugammadex, a selective relaxant binding agent, offers effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block. Anesthesiology 2007; 106:283–8Suy, K Morias, K Cammu, G Hans, P van Duijnhoven, WG Heeringa, M Demeyer, I
Vanacker BF, Vermeyen KM, Struys MMRF, Rietbergen H, Vandermeersch E, Saldien V, Kalmar AF, Prins ME: Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007; 104:563–8Vanacker, BF Vermeyen, KM Struys, MMRF Rietbergen, H Vandermeersch, E Saldien, V Kalmar, AF Prins, ME
Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS: Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: An international, multi-center, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008; 109:188–97Pühringer, FK Rex, C Sielenkämper, AW Claudius, C Larsen, PB Prins, ME Eikermann, M Khuenl-Brady, KS
Groudine SB, Soto R, Lien C, Drover D, Roberts K: A randomized, dose-finding phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104:555–62Groudine, SB Soto, R Lien, C Drover, D Roberts, K
Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, Velik-Salchner C, Wierda JM: Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Anesthesiology 2007; 106:935–43Sparr, HJ Vermeyen, KM Beaufort, AM Rietbergen, H Proost, JH Saldien, V Velik-Salchner, C Wierda, JM
de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M: Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: A multicenter, dose-finding and safety study. Anesthesiology 2007; 107:239–44de Boer, HD Driessen, JJ Marcus, MA Kerkkamp, H Heeringa, M Klimek, M
Naguib M, Lien CA, Aker J, Eliazo R: Posttetanic potentiation and fade in the response to tetanic and train-of-four stimulation during succinylcholine-induced block. Anesth Analg 2004; 98:1686–91Naguib, M Lien, CA Aker, J Eliazo, R
El-Orbany MI, Joseph NJ, Salem MR, Klowden AJ: The neuromuscular effects and tracheal intubation conditions after small doses of succinylcholine. Anesth Analg 2004; 98:1680–5El-Orbany, MI Joseph, NJ Salem, MR Klowden, AJ
Naguib M, Samarkandi A, Riad W, Alharby SW: Optimal dose of succinylcholine revisited. Anesthesiology 2003; 99:1045–9Naguib, M Samarkandi, A Riad, W Alharby, SW
Naguib M, Samarkandi AH, El-Din ME, Abdullah K, Khaled M, Alharby SW: The dose of succinylcholine required for excellent endotracheal intubating conditions. Anesth Analg 2006; 102:151–5Naguib, M Samarkandi, AH El-Din, ME Abdullah, K Khaled, M Alharby, SW
Simpson J, Munro PT, Graham CA: Rapid sequence intubation in the emergency department: 5 year trends. Emerg Med J 2006; 23:54–6Simpson, J Munro, PT Graham, CA
Dibble C, Maloba M: Rapid sequence induction in the emergency department by emergency medicine personnel. Emerg Med J 2006; 23:62–4Dibble, C Maloba, M
Fig. 1. Patient flow through the study. * According to the randomization schedule, this patient should have received rocuronium-sugammadex, but in error received succinylcholine. The patient was included in the succinylcholinetreated population, but in the intent-totreat population for rocuronium-sugammadex. † According to the randomization schedule, these two patients should have received succinylcholine, but in error received rocuronium-sugammadex. They were included in the rocuronium-sugammadex–treated population, but in the intent-totreat population for succinylcholine. 
Fig. 1. Patient flow through the study. * According to the randomization schedule, this patient should have received rocuronium-sugammadex, but in error received succinylcholine. The patient was included in the succinylcholinetreated population, but in the intent-totreat population for rocuronium-sugammadex. † According to the randomization schedule, these two patients should have received succinylcholine, but in error received rocuronium-sugammadex. They were included in the rocuronium-sugammadex–treated population, but in the intent-totreat population for succinylcholine. 
Fig. 1. Patient flow through the study. * According to the randomization schedule, this patient should have received rocuronium-sugammadex, but in error received succinylcholine. The patient was included in the succinylcholinetreated population, but in the intent-totreat population for rocuronium-sugammadex. † According to the randomization schedule, these two patients should have received succinylcholine, but in error received rocuronium-sugammadex. They were included in the rocuronium-sugammadex–treated population, but in the intent-totreat population for succinylcholine. 
×
Table 1. Time (min) from Start of Administration of Neuromuscular Blocking Agent to Recovery of T1to 10% and T1to 90% 
Image not available
Table 1. Time (min) from Start of Administration of Neuromuscular Blocking Agent to Recovery of T1to 10% and T1to 90% 
×
Table 2. Number of Patients with at Least One Adverse Event Regardless of Relationship to Study Drug 
Image not available
Table 2. Number of Patients with at Least One Adverse Event Regardless of Relationship to Study Drug 
×